N-Oleoyl glycine, a lipoamino acid, stimulates adipogenesis associated with activation of CB1 receptor and Akt signaling pathway in 3T3-L1 adipocyte

Biochem Biophys Res Commun. 2015 Oct 23;466(3):438-43. doi: 10.1016/j.bbrc.2015.09.046. Epub 2015 Sep 10.

Abstract

Adipose tissue plays a vital role in the development of obesity and related diseases. The aim of the present study was to investigate the effects of N-Oleoyl glycine (OLGly), a lipoamino acid, on 3T3-L1 adipogenesis and to explore the likely mechanisms underlying this process. Lipid accumulation were evaluated using Oil Red O staining and triglyceride content assay. The mRNA expressions of cannabinoid receptors and the protein expressions of adipogenic genes and intracellular signaling pathway were determined by real-time quantitative PCR and western blot, respectively. The results indicated that OLGly itself, but not its degradation products, stimulated lipid accumulation and significantly increased adipogenic genes (PPARγ and aP2), in a dose- and time-dependent manner. Additionally, OLGly markedly increased the mRNA expression of CB1 receptor (CB1R) and the inhibition of CB1R by its antagonist SR141716 abolished the promotive effects of OLGly on lipid accumulation and the protein expression of PPARγ and aP2. Furthermore, OLGly increased the ratio of p-Akt/Akt and p-FoxO1/FoxO1, which could be reversed by SR141716. Moreover, OLGly-induced enhancement of adipogenesis, activation of insulin-mediated Akt signaling pathway and inactivation of FoxO1 were effectively blocked by Wortmannin, a specific PI3K/Akt inhibitor, indicating the essential role of Akt signaling pathway in the process of OLGly-stimulated 3T3-L1 adipogenesis. In conclusion, OLGly, a lipoamino acid, was able to promote 3T3-L1 adipogenesis through the activation of CB1 receptor and the enhancement of insulin-mediated Akt signaling pathway. These findings suggested the potential role of OLGly in increasing insulin sensitivity and suppressing obesity and diabetes.

Keywords: 3T3-L1; Adipogenesis; Akt signaling pathway; CB1 receptor; Diabetes; OLGly.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3-L1 Cells
  • Adipocytes / cytology
  • Adipocytes / drug effects*
  • Adipocytes / metabolism*
  • Adipogenesis / drug effects*
  • Adipogenesis / genetics
  • Adipogenesis / physiology
  • Androstadienes / pharmacology
  • Animals
  • Cell Differentiation
  • Dose-Response Relationship, Drug
  • Fatty Acid-Binding Proteins / genetics
  • Glycine / administration & dosage
  • Glycine / analogs & derivatives*
  • Glycine / pharmacology
  • Insulin Resistance
  • Lipid Metabolism / drug effects
  • Mice
  • Oleic Acids / administration & dosage
  • Oleic Acids / pharmacology*
  • PPAR gamma / genetics
  • Protein Kinase Inhibitors / pharmacology
  • Proto-Oncogene Proteins c-akt / antagonists & inhibitors
  • Proto-Oncogene Proteins c-akt / metabolism*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Receptor, Cannabinoid, CB1 / agonists*
  • Receptor, Cannabinoid, CB1 / genetics
  • Signal Transduction / drug effects
  • Wortmannin

Substances

  • Androstadienes
  • Fabp4 protein, mouse
  • Fatty Acid-Binding Proteins
  • N-oleoylglycine
  • Oleic Acids
  • PPAR gamma
  • Protein Kinase Inhibitors
  • RNA, Messenger
  • Receptor, Cannabinoid, CB1
  • Proto-Oncogene Proteins c-akt
  • Glycine
  • Wortmannin